MIRM logo

Mirum Pharmaceuticals Inc. (MIRM)

$93.72

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on MIRM

Market cap

$6.12B

EPS

-15.46

P/E ratio

--

Price to sales

9.04

Dividend yield

--

Beta

0.758556

Price on MIRM

Previous close

$93.54

Today's open

$93.14

Day's range

$91.18 - $95.68

52 week range

$63.23 - $130

Profile about MIRM

CEO

Christopher Peetz

Employees

433

Headquarters

Foster City, CA

Exchange

NASDAQ Global Market

Shares outstanding

65282044

Issue type

Common Stock

MIRM industries and sectors

Healthcare

Biotechnology & Life Sciences

News on MIRM

GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing.

news source

Business Wire • Nov 5, 2026

news preview

Mirum Pharmaceuticals Q3 Earnings Call Highlights

Mirum Pharmaceuticals NASDAQ: MIRM reported third-quarter net product sales of $186 million and raised its full-year 2026 net product sales guidance to $715 million to $720 million, citing continued growth of LIVMARLI and its bile acid medicines as well as progress across its late-stage pipeline.

news source

MarketBeat • Nov 4, 2026

news preview

Mirum Pharmaceuticals, Inc. (MIRM) Q3 2026 Earnings Call Transcript

Mirum Pharmaceuticals, Inc. ( MIRM ) Q3 2026 Earnings Call November 3, 2026 4:30 PM EST Company Participants Andrew McKibben - Senior Vice President, Strategic Finance & Investor Relations Christopher Peetz - CEO & Director Peter Radovich - COO & President Rob Myers - Chief Medical Officer Eric Bjerkholt - Chief Financial Officer Conference Call Participants Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Luke Herrmann - Robert W. Baird & Co. Incorporated, Research Division Yesha Patel - Evercore ISI Institutional Equities, Research Division Kalpit Patel - Wolfe Research, LLC Ryan Deschner - Raymond James & Associates, Inc., Research Division James Condulis - Stifel, Nicolaus & Company, Incorporated, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Yigal Nochomovitz - Citigroup Inc., Research Division Michael Ulz - Morgan Stanley, Research Division Lisa Walter - RBC Capital Markets, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division Charles Wallace - H.C.

news source

Seeking Alpha • Nov 4, 2026

news preview

Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update.

news source

Business Wire • Nov 3, 2026

news preview

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates

Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.87 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to earnings of $0.05 per share a year ago.

news source

Zacks Investment Research • Nov 3, 2026

news preview

Here's What Key Metrics Tell Us About Mirum Pharmaceuticals (MIRM) Q3 Earnings

While the top- and bottom-line numbers for Mirum Pharmaceuticals (MIRM) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

news source

Zacks Investment Research • Nov 3, 2026

news preview

Mirum Pharmaceuticals Showcases Momentum Across Rare Liver Disease Portfolio with New Data at AASLD's The Liver Meeting® 2026

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Showcases Momentum Across Rare Liver Disease Portfolio with New Data at AASLD's The Liver Meeting® 2026.

news source

Business Wire • Nov 2, 2026

news preview

Mirum Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 3, 2026

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 3, 2026.

news source

Business Wire • Oct 27, 2026

news preview

Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

news source

Zacks Investment Research • Oct 27, 2026

news preview

Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Patients Aged 6 to

news source

Business Wire • Oct 26, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Mirum Pharmaceuticals Inc.

Open an M1 investment account to buy and sell Mirum Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in MIRM on M1